Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports

02.04.2024 | REVIEW

Prostate Cancer Diagnosis and Treatment for Patients with Neurogenic Bladder: Does the Literature Support a Different Approach?

verfasst von: M. P. Bigarella, K. A. Richards

Erschienen in: Current Bladder Dysfunction Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

In this review, the current literature available to patients and providers on the diagnosis and management of prostate cancer in patients with neurogenic bladder will be discussed. Topics include prostate cancer screening and diagnosis, radical prostatectomy and radiotherapy for prostate cancer, as well as surveillance.

Recent Findings

Neurogenic lower urinary tract dysfunction (NLUTD) patients are living longer due to better care, and cancer is becoming more frequent. This is partly due to the aging of this population, as well as intrinsic factors related to the underlying condition or urinary diversion, which poses them a greater risk of developing genitourinary malignancies. Although multiple studies have investigated this patient population, most are derived from large cohorts of spinal cord injury patients.

Summary

Many studies reported how PSA changes for different NGB patients. Few studies have investigated the management of prostate cancer, and good quality evidence for tailoring the care of this population is lacking. Although more evidence is available, improvement is still needed in using biomarkers for early diagnosis, specific screening protocols for different underlying conditions and urinary diversion, and standardized treatment recommendations based on long-term follow-up and surveillance.
Literatur
1.
Hartkopp A, et al. Survival and cause of death after traumatic spinal cord injury. A long-term epidemiological survey from Denmark. Spinal Cord. 1997;35(2):76–85.CrossRefPubMed
2.
Brandes SB, et al. Renal cell carcinoma in patients with prior spinal cord injury. J Spinal Cord Med. 2001;24(4):251–6.CrossRefPubMed
3.
Ismail S, et al. Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: a systematic review. Neurourol Urodyn. 2018;37(4):1386–95.CrossRefPubMed
4.
Nahm LS, et al. Bladder cancer mortality after spinal cord injury over 4 decades. J Urol. 2015;193(6):1923–8.CrossRefPubMed
5.
6.
Scott PA Sr, et al. Prostate cancer diagnosed in spinal cord-injured patients is more commonly advanced stage than in able-bodied patients. Urology. 2004;63(3):509–12.CrossRefPubMed
7.
Strauss DJ, et al. Trends in life expectancy after spinal cord injury. Arch Phys Med Rehabil. 2006;87(8):1079–85.CrossRefPubMed
8.
Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60(1):78–83.CrossRefPubMed
9.
Frisbie JH, Binard J. Low prevalence of prostatic cancer among myelopathy patients. J Am Paraplegia Soc. 1994;17(3):148–9.CrossRefPubMed
10.••
Barbonetti A, et al. Risk of prostate cancer in men with spinal cord injury: a systematic review and meta-analysis. Asian J Androl. 2018;20(6):555–60. Recent Meta-analysis of prostate cancer risk in SCI. Highlights rates of cancer detection, and characteristics of disease staging for this subset of patients. It showed a reduction in prostate cancer risk in SCI than controls.CrossRefPubMedPubMedCentral
11.
Bauman WA, et al. Metabolic and endocrine changes in persons aging with spinal cord injury. Assist Technol. 1999;11(2):88–96.CrossRefPubMed
12.
Huang TS, et al. Impaired hypothalamus-pituitary-adrenal axis in men with spinal cord injuries. Am J Phys Med Rehabil. 1998;77(2):108–12.CrossRefPubMed
13.
Safarinejad MR. Level of injury and hormone profiles in spinal cord-injured men. Urology. 2001;58(5):671–6.CrossRefPubMed
14.
Bartoletti R, et al. Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. Eur Urol. 2009;56(1):142–8.CrossRefPubMed
15.
Hvarness H, Jakobsen H, Biering-Sorensen F. Men with spinal cord injury have a smaller prostate than men without. Scand J Urol Nephrol. 2007;41(2):120–3.CrossRefPubMed
16.
Lee WY, et al. Risk of prostate and bladder cancers in patients with spinal cord injury: a population-based cohort study. Urol Oncol. 2014;32(1):51-e1-7.CrossRef
17.
Pannek J, et al. Prostate volume in male patients with spinal cord injury: a question of nerves? BJU Int. 2013;112(4):495–500.CrossRefPubMed
18.
Zermann DH, et al. Central nervous system neurons labeled following the injection of pseudorabies virus into the rat prostate gland. Prostate. 2000;44(3):240–7.CrossRefPubMed
19.
Shin YS, et al. Prostate volume and prostate-specific antigen in men with Parkinson’s disease are not different compared to age-matched control group: a prospective, case-controlled multicenter study. Prostate Int. 2015;3(2):62–4.CrossRefPubMedPubMedCentral
20.
Bowman RM, et al. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg. 2001;34(3):114–20.CrossRefPubMed
21.
22.•
Johnston AW, et al. Patterns of inpatient care for prostate cancer in men with spina bifida. Disabil Health J. 2020;13(2):100866. Clinical database analysis of prostate cancer in spina bifida patients, showing the trends of care in the care of SB population (from 1998 to 2014, extracted from National Inpatient Sample from the Healthcare Cost and Utilization Project. 
23.
Wiener JS, Frimberger DC, Wood H. Spina Bifida health-care guidelines for men’s health. Urology. 2018;116:218–26.CrossRefPubMed
24.
Eastham JA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, part II: principles of Active surveillance, principles of surgery, and follow-up. J Urol. 2022;208(1):19–25.CrossRefPubMed
25.
Eastham JA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208(1):10–8.CrossRefPubMed
26.
Eastham JA, et al. Clinically localized prostate cancer: AUA/ASTRO guideline. Part III: Principles of radiation and future directions. J Urol. 2022;208(1):26–33.CrossRefPubMed
27.
Eastham JA, Boorjian SA, Kirkby E. Clinically localized prostate cancer: AUA/ASTRO guideline. J Urol. 2022;208(3):505–7.CrossRefPubMed
28.
Lowrance W, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082–90.CrossRefPubMed
29.••
Schaeffer EM, et al. Prostate cancer, version 42023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(10):1067–96. Most recent prostate cancer guidelines for prostate cancer care according to The National Comprehensive Cancer Network. CrossRefPubMed
30.
Wei JT, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):46–53.CrossRefPubMed
31.
Wei JT, et al. Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy. J Urol. 2023;210(1):54–63.CrossRefPubMed
32.
Crawford ED, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011;29(4):355–61.CrossRefPubMed
33.
Chen RC, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA. 2017;317(11):1141–50.CrossRefPubMedPubMedCentral
34.
Gammon SR, et al. Surgical treatment for prostate cancer in patients with prior spinal cord injury. Ann Surg Oncol. 2005;12(8):674–8.CrossRefPubMed
35.
Leach GE, et al. Post-prostatectomy incontinence: urodynamic findings and treatment outcomes. J Urol. 1996;155(4):1256–9.CrossRefPubMed
36.
Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol. 2004;171(6 Pt 1):2128–37.CrossRefPubMed
37.
Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer. 1994;74(9):2520–32.CrossRefPubMed
38.
Quek ML, et al. Combined radical prostatectomy and bladder augmentation for concomitant prostate cancer and detrusor instability. Urology. 2005;65(5):964–7.CrossRefPubMed
39.
Harper ME, Pierrepoint CG, Griffiths K. Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol. 1984;20(4):477–82.CrossRefPubMed
40.
Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol. 1997;20(6):605–8.CrossRefPubMed
41.••
National Spinal Cord Injury Statistical Center. Spinal cord injury facts and figures at a glance. J Spinal Cord Med. 2013:36(1):1-2. https://​doi.​org/​10.​1179/​1079026813Z.​000000000136. Most updated statistics for SCI patients in the US, with median age of presentation, overall survival. This data sheet is a quick reference on demographic and condition status for 36,275 person with tSCI collected through 2022 by 31 federally funded SCI Model Systems
Metadaten
Titel
Prostate Cancer Diagnosis and Treatment for Patients with Neurogenic Bladder: Does the Literature Support a Different Approach?
verfasst von
M. P. Bigarella
K. A. Richards
Publikationsdatum
02.04.2024
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-024-00746-6

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise